Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ALMS by emailGet an email when ALMS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ALMS, unsubscribe in one click. Privacy
📣 What ALMS Says Is Next
fourth quarter of 2026 · “Alumis has reported positive results from its Phase 3 ONWARD program of envudeucitinib in moderate-to-severe plaque psoriasis and plans to file an NDA in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”
Company press release, Sep 1, 2026 · SEC filing
fourth quarter of this year · ““We are actively evaluating opportunities to maximize the value of our oral TYK2 portfolio and remain on track to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of this year.” Conference Call, Presentation and Webcast Details Alumis will host a webcast for the investment community to review the Phase 2 LUMUS results which will begin at 5:30 am PDT / 8:30 am EDT on Tuesday, September 1, 2026.”
Company press release, Sep 1, 2026 · SEC filing
in 2027 · “Next clinical candidate (new target) o Alumis now expects to initiate a clinical trial for the next clinical candidate in 2027 Second Quarter 2026 Financial Results”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ALMS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALMS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.